Protective effect of harmalol and harmaline on MPTP neurotoxicity in the mouse and dopamine-induced damage of brain mitochondria and PC12 cells

Journal of Neurochemistry

Volumn 75, Issue 2, 2000, Pages 521-531

  Lee, Chung Soo ^a   Han, Eun Sook ^a   Jang, Yoon Young ^a   Han, Jeong Ho ^b   Ha, Hyun Wook ^b   Kim, Doo Eung ^b  

^a Chung Ang University   (South Korea)

^b Korean Veterans Hospital   (South Korea)

Author keywords

Carbolines; Dopamine; MPTP; Neuroprotection

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; 2 DEOXYRIBOSE; AMINE OXIDASE (FLAVIN CONTAINING); CARBONYL DERIVATIVE; CATALASE; DOPAMINE; GLUTATHIONE PEROXIDASE; HARMALINE; HARMALOL; HARMINE; MALONALDEHYDE; REACTIVE OXYGEN METABOLITE; SUPEROXIDE DISMUTASE; THIOL;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BRAIN INJURY; CELL DEATH; CELL MEMBRANE POTENTIAL; CELL STRAIN; CONTROLLED STUDY; CYTOTOXICITY; DISORDERS OF MITOCHONDRIAL FUNCTIONS; ELECTRON TRANSPORT; ENZYME ACTIVITY; MALE; MOUSE; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; RAT;

1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; ANIMALS; BRAIN; DOPAMINE; ELECTRON TRANSPORT; FREE RADICAL SCAVENGERS; HARMALINE; INTRACELLULAR MEMBRANES; LIPID PEROXIDATION; MALE; MEMBRANE POTENTIALS; MICE; MICE, INBRED ICR; MITOCHONDRIA; MPTP POISONING; NEUROPROTECTIVE AGENTS; PC12 CELLS; RATS;

ANIMALIA;

EID: 0343081001     PISSN: 00223042     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1471-4159.2000.0750521.x     Document Type: Article

References (78)

1. Aebi H. (1984) Catalase in vitro. Methods Enzymol. 105, 121-126.
2. Airaksinen M. M. and Kari I. (1981) β-Carbolines, psychoactive compounds in the mammalian body. Part I: Occurrence, origin and metabolism. Mol. Biol. 59, 21-34.
3. Alam Z. I., Daniel S. E., Lees A. J., Marsden D. C., Jenner P., and Halliwell B. (1997) A generalized increase in protein carbonyls in the brain in Parkinson's but not incidental Lewy body disease. J. Neurochem. 69, 1326-1329.
4. Albores R., Neafsey E. J., Drucker G., Fields J. Z., and Collins M. A. (1990) Mitochondrial respiratory inhibition by N-methylated β-carboline derivatives structurally resembling N-methyl-4-phenylpyridine. Proc. Natl. Acad. Sci. USA 87, 9368-9372.
5. Aruoma O. I. (1994) Deoxyribose assay for detecting hydroxyl radicals. Methods Enzymol. 233, 57-66.
6. Banaclocha M. M., Hernandez A. I., Martinez N., and Ferrandiz M. L. (1997) N-Acetylcysteine protects against age-related increase in oxidized proteins in mouse synaptic mitochondria. Brain Res. 762, 256-258.
7. Barbaccia M. L., Ravizza L., and Costa E. (1986) Maprotiline: an antidepressant with an unusual pharmacological profile. J. Pharmacol. Exp. Ther. 236, 307-312.
8. Baum S. S., Hill R., and Rommelspacher H. (1996) Harman-induced changes of extracellular concentrations of neurotransmitters in the nucleus accumbens of rats. Eur. J. Pharmacol. 314, 75-82.
9. Berman S. B. and Hastings T. G. (1999) Dopamine oxidation alters mitochondrial respiration and induces permeability transition in brain mitochondria: implications for Parkinson's disease. J. Neurochem. 73, 1127-1137.
10. Buege J. A. and Aust S. D. (1978) Microsomal lipid peroxidation. Biomembranes. Methods Enzymol. 52, 302-310.
11. Burns R. S., Chiueh C. C., Markey S. P., Elbert M. H., Jacobowitz, D., and Kopin I. J. (1983) A primate model of parkinsonism: selective destruction of dopaminergic neurons in the pars compacta of the substantia nigra by N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Proc. Natl. Acad. Sci. USA 80, 4546-4550.
12. Cassarino D. S., Fall C. P., Swerdlow R. H., Smith T. S., Halvorsen E. M., Miller S. W., Parks J. P., Parker W. D. Jr., and Bennet J. P. Jr. (1997) Elevated reactive oxygen species and antioxidant enzyme activities in animal and cellular models of Parkinson's disease. Biochim. Biophys. Acta 1362, 77-80.
13. Cassarino D. S., Fall C. P., Smith T. S., and Bennet J. P. Jr. (1998) Pramipexole reduces reactive oxygen species production in vivo and in vitro and inhibits the mitochondrial permeability transition produced by the parkinsonian neurotoxin methylpyridinium ion. J. Neurochem. 71, 295-301.
14. + opens the mitochondrial permeability transition pore and releases cytochrome c in isolated mitochondria via an oxidative mechanism. Biochim. Biophys. Acta 1453, 49-62.
15. Chiueh C. C., Wu R. M., Mohanakumar K. P., Sternberger L. M., Krishna G., Obata T., and Murphy D. L. (1994) In vivo generation of hydroxyl radicals and MPTP-induced dopaminergic toxicity in the basal ganglia. Ann. NY Acad. Sci. 738, 25-36.
16. 2. Korean J. Pharmacol. 31, 345-353.
17. Clark J. B. and Nicklas W. J. (1970) The metabolism of rat brain mitochondria. Preparation and characterization. J. Biol. Chem. 245, 4724-4731.
18. + in PC12 cells: insights into potential neurotoxicants in Parkinson's disease. J. Neurochem. 62, 1503-1510.
19. Cohen G. and Kesler N. (1999) Monoamine oxidase and mitochondrial respiration. J. Neurochem. 73, 2310-2315.
20. Cohen G., Farooqui R., and Kesler N. (1997) Parkinson disease: a new link between monoamine oxidase and mitochondrial electron flow. Proc. Natl. Acad. Sci. USA 94, 4890-4894.
21. Cohen H. J. and Chovaniec M. E. (1978) Superoxide generation by digitonin-stimulated guinea pig granulocytes. A basis for a continuous assay for monitoring superoxide production and for the study of the activation of the generating system. J. Clin. Invest. 61, 1081-1087.
22. Davis G. C., Williams A. C., Markey S. P., Elbert M. H., Caine E. D., Reichert C. M., and Kopin I. P. (1979) Chronic parkinsonism secondary to intravenous injection of meperidine analogues. Psychiatr. Res. 1, 249-254.
23. d'Ischia M., Constantini C., and Prota G. (1993) Reaction of dopamine with malondialdehyde: a possible underlying event in Parkinson's disease. Tetrahedron Lett. 34, 3921-3924.
24. Du Y., Dodel R. C., Bales K. R., Jemmerson R., Hamilton-Byrd E., and Paul S. M. (1997) Involvement of a caspase-3-like cysteine protease in 1-methyl-4-phenylpyridinium-mediated apoptosis of cultured cerebellar granule neurons. J. Neurochem. 69, 1382-1388.
25. Ebadi M., Srinivasan S. K., and Baxi M. D. (1996) Oxidative stress and antioxidant therapy in Parkinson's disease. Prog. Neurobiol. 48, 1-19.
26. Fernandez de Arriva A., Lizcano J. M., Balsa M. D., and Unzeta M. (1994) Inhibition of monoamine oxidase from bovine retina by β-carbolines. J. Pharm. Pharmacol. 46, 809-813.
27. Flohe L. and Gunzler W. A. (1984) Assays of glutathione peroxidase. Methods Enzymol. 105, 114-121.
28. Fornai F., Vaglini F., Maggio R., Bonuccelli U., and Corsini G. U. (1996) Excitatory amino acids and MPTP toxicity. Adv. Neurol. 69, 167-176.
29. Fu W., Luo H., Parthasarathy S., and Mattson M. P. (1998) Catecholamines potentiate amyloid β-peptide neurotoxicity: involvement of oxidative stress, mitochondrial dysfunction, and perturbed calcium homeostasis. Neurobiol. Dis. 5, 229-243.
30. Fuller R. W., Wong C. J., and Hemrick-Luecke S. K. (1986) MD 240928 and harmaline: opposite selectivity in antagonism of the inactivation of types A and B monoamine oxidase by pargyline in mice. Life Sci. 38, 409-412.
31. Graham D. G. (1984) Catecholamine toxicity: a proposal for the molecular pathogenesis of manganese neurotoxicity and Parkinson's disease. Neurotoxicology 5, 83-95.
32. Graham D. G., Tiffany S. M., Bell W. R., and Gutknecht W. F. (1978) Autoxidation versus covalent binding of quinones as the mechanism of toxicity of dopamine, 6-hydroxydopamine, and related compounds towards C1300 neuroblastoma cells in vitro. Mol. Pharmacol. 14, 644-653.
33. Gutteridge J. M. C., Rowley D. A., and Halliwell B. (1982) Superoxide dependent formation of hydroxyl radicals and lipid peroxidation in the presence of iron salts. Detection of 'catalytic' iron and antioxidant activity in extracellular fluids. Biochem. J. 206, 605-609.
34. Halliwell B. and Gutteridge J. M. C. (1999) Detection of free radicals and other reactive species: trapping and fingerprinting, in Free Radicals in Biology and Medicine, 3rd edit. (Halliwell B. and Gutteridge J. M. C., eds). pp. 351-429. Oxford University Press, New York.
35. Heikkila R. E., Hess A., and Duvoisin R. C. (1984) Dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in mice. Science 224, 467-469.
36. Hoyt K. R., Reynolds I. J., and Hastings T. G. (1997) Mechanisms of dopamine-induced cell death in cultured rat forebrain neurons: interactions with and differences from glutamate-induced cell death. Exp. Neurol. 143, 269-281.
37. Hung H. C. and Lee E. H. Y. (1998) MPTP produces differential oxidative stress and antioxidative responses in the nigrostriatal and mesolimbic dopaminergic pathways. Free Radic. Biol. Med. 24, 76-84.
38. Jellinger K. A. (1999) The role of iron in neurodegeneration: prospects for pharmacotherapy of Parkinson's disease. Drugs Aging 14, 115-140.
39. Kim H. H., Jang Y. Y., Han E. S., and Lee C. S. (1999) Differential antioxidant effects of ambroxol, rutin, glutathione and harmaline. J. Appl. Pharmacol. 7, 112-120.
40. 2+ transport by dopamine oxidation. Mol. Cell. Biochem. 201, 88-96.
41. Kim-Han J. S. and Sun A. Y. (1998) Protection of PC12 cells by glutathione peroxidase in L-DOPA induced cytotoxicity. Free Radic. Biol. Med. 25, 512-518.
42. Koh J. Y., Han E. S., and Lee C. S. (1998) Protective action of ambroxol on the oxidative damages of lipid, hyaluronic acid and collagen. J. Appl. Pharmacol. 6, 111-118.
43. Koller W. C. (1997) Neuroprotective therapy for Parkinson's disease. Exp. Neurol. 144, 24-28.
44. Kuhn W., Muller T., Grosse H., and Rommelspacher H. (1995) Plasma harman and norharman in Parkinson's disease. J. Neural. Transm. Suppl. 46, 291-295.
45. Kuhn W., Muller T., Grosse H., and Rommelspacher H. (1996) Elevated levels of harman and norharman in cerebrospinal fluid of parkinsonian patients. J. Neural Transm. 103, 1435-1440.
46. Lai C.-T. and Yu P. H. (1997) Dopamine-and L-β-3,4-dihydroxyphenylalanine hydrochloride (L-DOPA)-induced cytotoxicity towards catecholaminergic neuroblastoma SH-SY5Y cells. Effects of oxidative stress and antioxidative factors. Biochem. Pharmacol. 53, 363-372.
47. Levine R. L., Garland D., Oliver C. N., Amici A., Climent I., Lenz A.-G., Ahn B.-W., Shaltiel S., and Stadman E. R. (1990) Determination of carbonyl content in oxidatively modified proteins. Methods Enzymol. 186, 464-478.
48. Li C. L., Werner P., and Cohen G. (1995) Lipid peroxidation in brain: interactions of L-DOPA/dopamine with ascorhate and iron. Neurodegeneration 4, 147-153.
49. Linert W., Herlinger E., Jameson R. F., Kienzl E., Jellinger K., and Youdim M. B. (1996) Dopamine, 6-hydroxydopamine, iron, and dioxygen - their mutual interactions and possible implication in the development of Parkinson's disease. Biochim. Biophys. Acta 1316, 160-168.
50. Loew G. H., Nienow J., Lawson J. A., Toll L., and Uyeno E. T. (1985) Theoretical structure-activity studies of β-carboline analogs. Requirements for benzodiazepine receptor affinity and antagonist activity. Mol. Pharmatol. 28, 17-31.
51. Lotharius J., Dugan L. L., and O'Malley K. L. (1999) Distinct mechanisms underlie neurotoxin-mediated cell death in cultured dopaminergic neurons. J. Neurochem. 19, 1284-1293.
52. McCord J. M. and Fridovich I. (1969) Superoxide dismutase. Enzymatic function for erythrocuprein (hemocuprein). J. Biol. Chem. 244, 6049-6055.
53. McLaughlin B. A., Nelson D., Erecińska M., and Chesselet M.-F. (1998) Toxicity of dopamine to striatal neurons in vitro and potentiation of cell death by a mitochondrial inhibitor. J. Neurochem. 70, 2406-2415.
54. Miura T., Muraoka S., and Ogiso T. (1998) Antioxidant activity of adrenergic agents derived from catechol. Biochem. Pharmacol. 55, 2001-2006.
55. Mosmann T. (1983) Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J. Immunol. Methods 65, 55-63.
56. Ochu E. E., Rothwell N. J., and Waters C. M. (1998) Caspases mediate 6-hydroxydopamine-induced apoptosis but not necrosis in PC12 cells. J. Neurochem. 70, 2637-2640.
57. Offen D., Ziv I., Sternin H., Melamed E., and Hochman A. (1996) Prevention of dopamine-induced cell death by thiol antioxidants: possible implications for treatment of Parkinson's disease. Exp. Neurol. 141, 32-39.
58. O'Hearn E. and Molliver M. E. (1993) Degeneration of Purkinje cells in parasagittal zones of the cerebellar vermis after treatment with ibogaine or harmaline. Neuroscience 55, 303-310.
59. O'Hearn E. and Molliver M. E. (1997) The olivocerebellar projection mediates ibogaine-induced degeneration of Purkinje cells: a model of indirect, trans-synaptic excitotoxicity. J. Neurosci. 17, 8828-8841.
60. Olanow C. and Arendash G. (1994) Metals and free radicals in neurodegeneration. Curr. Opin. Neurol. 7, 548-558.
61. Przedborski S., Kostic V., Jackson-Lewis V., Naini A. B., Simonetti S., Fahn S., Carlson E., Epstein C. J., and Cadet J. L. (1992) Transgenic mice with increased Cu/Zn-superoxide dismutase activity are resistant to N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity. J. Neurosci. 12, 1658-1667.
62. Rabinovic A. D. and Hastings T. G. (1998) Role of endogenous glutathione in the oxidation of dopamine. J. Neurochem. 71, 2071-2078.
63. Schapira A. H. (1999) Mitochondrial involvement in Parkinson's disease, Huntington's disease, hereditary spastic paraplegia and Friedreich's ataxia. Biochim. Biophys. Acta 1410, 159-170.
64. Schulz J. B., Matthews R. T., Klockgether T., Dichgans J., and Beal M. F. (1997) The role of mitochondrial dysfunction and neuronal nitric oxide in animal models of neurodegenerative diseases. Mol. Cell. Biochem. 174, 193-197.
65. Seaton T. A., Cooper J. M., and Schapira A. H. (1997) Free radical scavengers protect dopaminergic cell lines from apoptosis induced by complex I inhibitors. Brain Res. 777, 110-118.
66. Simonian N. A. and Coyle J. T. (1996) Oxidative stress in neurodegenerative diseases. Anna. Rev. Pharmacol. Toxicol. 36, 83-106.
67. Smith T. S. and Bennett J. P. Jr. (1997) Mitochondrial toxins in models of neurodegenerative diseases. I: In vivo brain hydroxyl radical production during systemic MPTP treatment or following microdialysis infusion of methylpyridium or azide ions. Brain Res. 765, 183-188.
68. Sofic E., Lange K. W., Jellinger K., and Riederer P. (1992) Reduced and oxidized glutathione in the substantia nigra of patients with Parkinson's disease. Neurosci. Lett. 142, 128-130.
69. Spencer J. P., Jenner A., Butler J., Aruoma O. I., Dexter D. T., Jenner P., and Halliwell B. (1996) Evaluation of the pro-oxidant and antioxidant actions of L-DOPA and dopamine in vitro: implications for Parkinson's disease. Free Radic. Res. 24, 95-105.
70. Stennicke H. R. and Salvesen G. S. (1999) Caspases: preparation and characterization. A Companion to Methods in Enzymology 17, 313-319.
71. Takai N., Nakanishi H., Tanabe K., Nishioku T., Sugiyama T., Fujiwara M., and Yamamoto K. (1998) Involvement of caspase-like proteinases in apoptosis of neuronal PC12 cells and primary cultured microglia induced by 6-hydroxydopamine. J. Neurosci. Res. 54, 214-222.
72. Tse S. Y. H., Mak I. T., and Dickens B. F. (1991) Antioxidative properties of harmane and β-carboline alkaloids. Biochem. Pharmacol. 42, 459-464.
73. Uyemura S. A., Santos A. C., Mingatto F. E., Jordani M. C., and Curti C. (1997) Diclofenac sodium and mefenamic acid: potent inducers of the membrane permeability transition in renal cortex mitochondria. Arch. Biochem. Biophys. 342, 231-235.
74. Velez-Pardo C., Jimenez Del Rio M., Verschueren H., Ebinger G., and Vauquelin G. (1997) Dopamine and iron induce apoptosis in PC12 cells. Pharmacol. Toxicol. 80, 76-84.
75. Walkinshaw G. and Waters C. M. (1995) Induction of apoptosis in catecholaminergic PC12 cells by L-DOPA. Implications for the treatment of Parkinson's disease. J. Clin. Invest. 95, 2458-2464.
76. Wudarczyk J., Debska G., and Lenartowicz E. (1999) Zinc as an inducer of the membrane permeability transition in rat liver mitochondria. Arch. Biochem. Biophys. 363, 1-8.
77. Yamakawa T. and Ohta S. (1999) Biosynthesis of a parkinsonism-preventing substance, 1-methyl-1,2,3,4-tetrahydroisoquinoline, is inhibited by parkinsonism-inducing compounds in rat brain mitochondrial fraction. Neurosci. Lett. 259, 157-160.
78. Ziv I., Offen D., Barzilai A., Haviv R., Stein R., Zilkha-Falb R., Shirvan A., and Melamed E. (1997) Modulation of control mechanisms of dopamine-induced apoptosis - a future approach to the treatment of Parkinson's disease? J. Neural. Transm. Suppl. 49, 195-202.